BrainQ Technologies news
WASHINGTON, Dec. 9, 2021 – BrainQ today announced that the first patient has been enrolled at MedStar National Rehabilitation Hospital in its pivotal, randomized, double-blind, multicenter trial, EMAGINE (the BQ5 Study). The trial is evaluating its frequency-tuned electromagnetic field treatment in facilitating recovery in individuals with moderately-sev
- Funding round led by Hanaco Ventures, joined by Dexcel Pharma and Peregrine Ventures, and existing investors.
- BrainQ’s investigational neurorecovery technology has been granted FDA Breakthrough Device Designation, and is set to be trialed in a multicenter pivotal study for stroke patients in select hospitals across the US.
Jerusalem, Israel – August 16, 2021 – Israeli stroke therapy technology startu
JERUSALEM, March 11, 2021 -- BrainQ, the Israeli start-up with an AI-powered therapeutic platform, today revealed the encouraging results of their Randomized Controlled Trial (RCT) which supported a recently granted request for FDA Breakthrough Device Designation. The pilot trial data will be presented as part of the International Stroke Conference between March 17-19.
In a single site, t
JERUSALEM, Feb. 11, 2021-- BrainQ, the Israeli start-up with a therapeutic solution to reduce disability following stroke, announced today that the United States Food and Drug Administration (FDA) has designated its AI-powered technology as a Breakthrough Device. The designation, which was based on BrainQ`s latest randomized controlled clinical trial results for ischemic stroke patients, provides BrainQ with the opportunity to work closely with the FDA to ex